Denali Therapeutics Inc.

This study looks at the long-term safety and effects of an experimental drug called DNL310 for people with Hunter syndrome (MPS II), a rare genetic disease. Participants who completed earlier studies can join and receive the drug for up to 5 years. The goal is to see if the drug …

This study tests a new drug called DNL126 in 20 children with Sanfilippo syndrome type A, a rare genetic disease that damages the brain and body. The goal is to see if the drug is safe and can lower harmful substances linked to the disease. The study lasts about 6 months, with op…

This study tests an experimental drug called DNL593 for frontotemporal dementia, a brain disease that affects personality and language. First, healthy volunteers receive a single dose to check safety. Then, people with the disease receive multiple doses over 25 weeks to see if th…